This case study shows how MedPharm developed a reconstructed nasal epithelium (RNE) model to improve prediction of nasal drug delivery performance. By replicating key physiological features and benchmarking against clinical data, the model generated more reliable, human-relevant data and supported better formulation decisions.
Advancing Nasal Drug Delivery Through Predictive Modeling (MedCast®)
This case study shows how MedPharm improved nasal drug delivery modeling using advanced in vitro systems, including reconstructed human nasal epithelium and CT-based nasal casts (MedCast®). These approaches generated more predictive data, improved in vitro to in vivo correlation, and supported better formulation and development decisions.
Resolving Scale-Up Stability Challenges Through Process Development
This case study shows how MedPharm resolved scale-up stability challenges by identifying process-driven root causes and optimizing manufacturing parameters. Through targeted studies and process optimization, variability was reduced and a robust, reproducible scale-up strategy was established.
Overcoming Solubility Challenges in Small Molecule Formulation
This case study shows how MedPharm solved solubility challenges in a small molecule formulation. The team identified the root cause of drug precipitation and optimized excipient selection. Through targeted solubility studies and formulation design, stability improved and regulatory risk was reduced. The result was a robust, scalable formulation that enabled continued development.
Stabilizing a Biologic for Nail Delivery
This case study demonstrates how MedPharm stabilized a biologic formulation for topical nail delivery by identifying root causes of instability and optimizing excipient selection. Through targeted degradation studies and formulation optimization, MedPharm improved stability, reduced development risk, and enabled progression to IND-enabling studies.
Expanding Formulation Space to Strengthen Intellectual Property
This case study highlights how MedPharm expanded formulation space to strengthen intellectual property and increase commercial value for a topical drug product. By developing and evaluating multiple formulation types, including gels, creams, ointments, and foams, MedPharm enabled broader patent coverage while maintaining consistent product performance. The result was a more defensible IP strategy, reduced competitive risk, and enhanced long-term asset value.
Assessment of Wound Healing Treatments with Long Term Skin Culture Methods & a Novel Wounding Device
This scientific poster explores advanced methods for assessing wound healing using long-term human skin culture models. By combining a novel wounding device with MedPharm’s Skin-Life Extension Preparation (SLEP) and high-throughput pharmacodynamic (HTPD) system, the study demonstrates improved consistency, extended culture duration, and more informative evaluation of inflammation, proliferation, and tissue remodeling in wound healing research.
Robustness of Ex Vivo, Human Skin as a Model of General Inflammation
This scientific poster explores ex vivo human skin as a model of general inflammation, highlighting its use for evaluating inflammatory responses across Th1, Th2, Th17, and LPS pathways. The data demonstrates how human skin models can support pathway differentiation, inhibitor assessment, and more predictive preclinical decision-making in inflammatory drug development.
Use of Reconstructed Tissue and 3D Printed CT-Based Nasal Casts for the Assessment of Nasal Delivery
This scientific poster explores advanced in vitro models for nasal drug delivery, including reconstructed nasal epithelium and CT-based 3D printed nasal casts (MedCast®). These approaches enable more predictive assessment of drug permeation, penetration, and regional distribution compared to traditional methods, supporting improved formulation selection and reducing risk in drug development.
Videos & Webinars – Test 01
Top placeholder text. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.